Brain natriuretic peptide as a cardiotoxicity biomarker in children with hematological malignancies

Minerva Pediatrica

Volumn 64, Issue 3, 2012, Pages 307-312

  Tragiannidis, A ^a   Dokos, C ^a   Tsotoulidou, V ^a   Giannopoulos, A ^a   Pana, Z D ^a   Papageorgiou, T ^a   Karamouzis, M ^a   Athanassiadou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anthracyclines; Hematological neoplasms; Natriuretic peptides

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; STATISTICAL ANALYSIS;

ALGORITHMS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84862559428     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Alvarez J, Scully R, Miller T, Armstrong FD, Constine LS, Friedman DL et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 2007;19:23-31.
2. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
3. Lipshultz SE, Alvarez J, Scully R. Anthracyclines associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33.
4. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
5. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
6. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.
7. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007;15:651-62.
8. Cox CL, Rai SN, Rosenthal D, Phipps S, Hudson MM. Subclinical late cardiac toxicity in childhood cancer survivors: impact on self-reported health. Cancer 2008;112:1835-44.
9. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
10. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
11. Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005;7:187-202.
12. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58.
13. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006;33(Suppl 8):S15-21.
14. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52.
15. Maeda K, Tsutamoto T, Wada A, Hisanga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
16. Maisel AS. B-type natriuretic peptide (BNP) levels: Diagnostic and therapeutic potential. Rev Cardiovasc Med 2001;2:S13-8.
17. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: A diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80.
18. AML Collaborative Group. A systemic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia. AML Collaborative Group. Br J Haematol 1998;103:100-9.
19. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980;62:1054-61.
20. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600-6.
21. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
22. Baughman KL. B-type natriuretic peptide-a window to the heart. N Engl J Med 2002;347:158-9.
23. Mir TS, Marohn S, Läer S, Eiselt M, Grollmus O, Weil J. Plasma concentration of N terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:76-86.
24. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8.
25. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9.
26. Ekstein S, Nir A, Rein A, Perles Z, Bar-Oz B, Salpeter L et al. N-terminal-proB-Type Natriuretic Peptide as a marker for acute anthracyclines cardiotoxicity in children. J Pediatr Hematol Oncol 2007;29:440-4.
27. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 2004;22:769-73.
28. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002;20:1677-82.
29. Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463-8.
30. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318-26.
31. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007;43:1959-66.